Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Pulmonology · Genetic Interstitial Lung Disease

Treatment Strategies and the Standard of Care

At a Glance

Treatment for genetic interstitial lung diseases (like ILD2) focuses on managing cellular stress and slowing lung scarring. Standard care includes supportive medications like hydroxychloroquine, anti-fibrotics for progressive fibrosis, and ongoing monitoring by a specialized multidisciplinary team.

Managing a genetic interstitial lung disease (ILD) like ILD2 (SFTPC mutation) or ABCA3 deficiency requires a shift in mindset. Because the root cause is a “manufacturing error” in the lungs rather than an external attack, the goal of treatment is to manage cellular stress, reduce inflammation, and slow down the formation of scar tissue [1][2].

The Current Standard of Care

Because these conditions are ultra-rare, there is no single, globally approved “cure.” Instead, specialized centers use a combination of therapies based on decades of clinical experience and the patient’s specific symptoms.

1. Etiology-Specific Supportive Care

For genetic surfactant disorders, doctors often use medications that attempt to stabilize the lung cells’ environment:

  • Hydroxychloroquine: Often the first line of defense, especially in children (chILD). It is believed to help the lung cells process the “misfolded” surfactant proteins more efficiently [3][4].
  • Systemic Corticosteroids: Sometimes used in “pulses” (high doses given periodically) to dampen sudden flares of inflammation, though their long-term benefit for genetic mutations is variable [4][5].
  • Azithromycin: While often used for its anti-inflammatory properties, its effectiveness in improving lung function in genetic ILD is still being studied and is not always guaranteed [6][7].

2. Managing Progressing Fibrosis

If the disease begins to cause permanent scarring (progressive fibrosing ILD), the focus may shift to anti-fibrotics:

  • Nintedanib and Pirfenidone: These are medications originally approved for idiopathic pulmonary fibrosis (IPF). However, nintedanib is now formally FDA-approved for chronic fibrosing interstitial lung diseases with a progressive phenotype (PF-ILD), which includes progressive genetic ILDs [8][9]. These medications work by blocking the signals that tell the body to build scar tissue [8].

Identifying Substandard Care

Because genetic ILDs are rare, a patient may encounter doctors who treat the condition like standard asthma or a simple infection. Be alert if:

  • Over-reliance on Inhalers: Bronchodilators (like albuterol) usually do not help genetic ILD because the problem is in the lung tissue, not the airways [10].
  • Lack of Genetic Context: If a doctor suggests aggressive immunosuppression (like those used for Lupus or Rheumatoid Arthritis) without acknowledging the genetic mutation, they may be treating the wrong underlying mechanism (unless you have a specific immune-related genetic mutation like COPA syndrome, where immunosuppression is appropriate) [11].
  • Wait-and-See Approach: In genetic ILD, “waiting and seeing” can allow permanent scarring to occur. Expert care involves active monitoring and early intervention [12].

The Treatment Decision Path

While every patient is different, care typically follows this general logic:

  1. Diagnosis: Confirm specific mutation (e.g., SFTPC, ABCA3) and current lung function [13].
  2. Initial Stabilization: Trial of hydroxychloroquine and/or steroids to reduce “cellular stress” [3].
  3. Advanced Monitoring: Regular high-resolution CT (HRCT) scans to check for new fibrosis (scarring) [14].
  4. Fibrosis Management: If scarring progresses, consider adding anti-fibrotic therapy [8].
  5. End-Stage Options: For severe, life-threatening cases, lung transplantation is a valid and often successful option for both children and adults [15][15].

The Importance of a Multidisciplinary Team

A “lone” doctor is rarely enough for genetic ILD. Expert care should involve:

  • A Pediatric or Adult Pulmonologist with experience in the chILD network or a specialized ILD center.
  • A Geneticist to help interpret mutations and screen family members.
  • A Specialized Radiologist who can recognize the subtle patterns of surfactant disorders on a CT scan [16].

Currently, while interventional clinical trials for these specific mutations may be rare, the landscape changes rapidly. Patients should routinely check trial registries (like ClinicalTrials.gov) and ask their care team about newly opening studies [17][18].

Common questions in this guide

What is the first-line medication for genetic ILDs like SFTPC or ABCA3?
Hydroxychloroquine is often used as a first-line treatment, especially for children. It is believed to help lung cells process misfolded surfactant proteins more efficiently and stabilize the cellular environment.
Will asthma inhalers help improve my genetic ILD symptoms?
Standard asthma treatments like bronchodilators generally do not help with genetic ILDs. This is because the underlying disease affects the lung tissue itself, rather than causing airway constriction.
When are anti-fibrotic medications used for genetic ILD?
If the disease causes progressive permanent scarring in the lungs, doctors may prescribe anti-fibrotic medications like nintedanib. These medications work by blocking the body's signals that build new scar tissue.
What kinds of specialists should be on my genetic ILD care team?
Expert care requires a multidisciplinary team. This typically includes a specialized pediatric or adult pulmonologist, a geneticist to interpret mutations, and a specialized radiologist who can recognize subtle ILD patterns on CT scans.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Does our current care team include a pulmonologist with experience specifically in genetic surfactant disorders or the chILD network?
  2. 2.Why are we choosing this specific medication (like hydroxychloroquine or steroids) for a genetic condition, and what specific improvement are we looking for?
  3. 3.If the disease is showing signs of progressive scarring (fibrosis), at what point should we consider starting anti-fibrotic medications like nintedanib?
  4. 4.What are the 'transition' benchmarks for moving from pediatric care to an adult ILD specialist as the patient grows?
  5. 5.Are there any active registries or observational trials we can join to contribute to research on this specific mutation?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (18)
  1. 1

    An SFTPC BRICHOS mutant links epithelial ER stress and spontaneous lung fibrosis.

    Katzen J, Wagner BD, Venosa A, et al.

    JCI insight 2019; (4(6)).

    PMID: 30721158
  2. 2

    Disruption of proteostasis causes IRE1 mediated reprogramming of alveolar epithelial cells.

    Katzen J, Rodriguez L, Tomer Y, et al.

    Proceedings of the National Academy of Sciences of the United States of America 2022; (119(43)):e2123187119 doi:10.1073/pnas.2123187119.

    PMID: 36252035
  3. 3

    Congenital Surfactant C Deficiency with Pulmonary Hypertension-A Case Report.

    Chua WC, Chen IC, Liu YC, et al.

    Children (Basel, Switzerland) 2022; (9(10)) doi:10.3390/children9101435.

    PMID: 36291368
  4. 4

    Delayed Presentation and Prolonged Survival of a Child with Surfactant Protein B Deficiency.

    López-Andreu JA, Hidalgo-Santos AD, Fuentes-Castelló MA, et al.

    The Journal of pediatrics 2017; (190()):268-270.e1 doi:10.1016/j.jpeds.2017.07.009.

    PMID: 28888561
  5. 5

    [Genetic variants in the surfactant protein C gene 218 site are associated with pediatric interstitial lung disease: seven cases study].

    Liu J, Chen JH, Wang YQ, et al.

    Zhonghua er ke za zhi = Chinese journal of pediatrics 2019; (57(1)):21-26 doi:10.3760/cma.j.issn.0578-1310.2019.01.007.

    PMID: 30630227
  6. 6

    Azithromycin alleviates the severity of rheumatoid arthritis by targeting the unfolded protein response component of glucose-regulated protein 78 (GRP78).

    Zhang Y, Ge L, Song G, et al.

    British journal of pharmacology 2022; (179(6)):1201-1219 doi:10.1111/bph.15714.

    PMID: 34664264
  7. 7

    Longitudinal lung function trajectories in response to azithromycin therapy for chronic lung disease in children with HIV infection: a secondary analysis of the BREATHE trial.

    Madanhire T, McHugh G, Simms V, et al.

    BMC pulmonary medicine 2024; (24(1)):339 doi:10.1186/s12890-024-03155-x.

    PMID: 38997676
  8. 8

    Real-world safety and effectiveness of pirfenidone and nintedanib in the treatment of idiopathic pulmonary fibrosis: a systematic review and meta-analysis.

    Kou M, Jiao Y, Li Z, et al.

    European journal of clinical pharmacology 2024; (80(10)):1445-1460 doi:10.1007/s00228-024-03720-7.

    PMID: 38963453
  9. 9

    Antifibrotic drugs in connective tissue disease-related interstitial lung disease (CTD-ILD): from mechanistic insights to therapeutic applications.

    Erre GL, Sebastiani M, Manfredi A, et al.

    Drugs in context 2021; (10()) doi:10.7573/dic.2020-8-6.

    PMID: 33505482
  10. 10

    An SFTPC gene mutation causes childhood interstitial lung disease: first report in the Arab region.

    Alzaid MA, Eltahir S, Amin Ur Rahman M, et al.

    JRSM open 2020; (11(2)):2054270419894821 doi:10.1177/2054270419894821.

    PMID: 32095252
  11. 11

    Imaging findings of COPA Syndrome.

    Nguyen HN, Salman R, Vogel TP, et al.

    Pediatric radiology 2023; (53(5)):844-853 doi:10.1007/s00247-023-05600-1.

    PMID: 36746811
  12. 12

    Surfactant protein C dysfunction with new clinical insights for diffuse alveolar hemorrhage and autoimmunity.

    Tang X, Shen Y, Zhou C, et al.

    Pediatric investigation 2019; (3(4)):201-206 doi:10.1002/ped4.12162.

    PMID: 32851322
  13. 13

    An update on diagnosis and treatments of childhood interstitial lung diseases.

    Marczak H, Krenke K, Griese M, et al.

    Breathe (Sheffield, England) 2025; (21(2)):250004 doi:10.1183/20734735.0004-2025.

    PMID: 40365093
  14. 14

    A rare interstitial lung disease in young adulthood due to surfactant protein C gene mutation: Two case reports with brief literature review.

    Sengul Y, Gosche E, Hazelton T

    Radiology case reports 2025; (20(9)):4299-4303 doi:10.1016/j.radcr.2025.05.051.

    PMID: 40575365
  15. 15

    Outcome of lung transplantation for adults with interstitial lung disease associated with genetic disorders of the surfactant system.

    Bermudez J, Nathan N, Coiffard B, et al.

    ERJ open research 2023; (9(6)) doi:10.1183/23120541.00240-2023.

    PMID: 38020562
  16. 16

    Rare genetic interstitial lung diseases: a pictorial essay.

    Borie R, Berteloot L, Kannengiesser C, et al.

    European respiratory review : an official journal of the European Respiratory Society 2024; (33(174)) doi:10.1183/16000617.0101-2024.

    PMID: 39537246
  17. 17

    Systematic review of drug effects in humans and models with surfactant-processing disease.

    Klay D, Hoffman TW, Harmsze AM, et al.

    European respiratory review : an official journal of the European Respiratory Society 2018; (27(149)) doi:10.1183/16000617.0135-2017.

    PMID: 29997245
  18. 18

    Engraftment of wild-type alveolar type II epithelial cells in surfactant protein C deficient mice.

    Predella C, Lapsley L, Ni K, et al.

    NPJ Regenerative medicine 2026; (11(1)):11 doi:10.1038/s41536-026-00455-0.

    PMID: 41554733

This page provides educational information about treatment strategies for genetic interstitial lung diseases. It does not replace professional medical advice from a specialized pulmonologist or care team.

Get notified when new evidence is published on Interstitial lung disease 2.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.